États-Unis · Plateformes & données · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Publié par Briefing.com · États-Unis il y a 14 j

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

Lire l'article complet sur Briefing.com Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.briefing.com)

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

À lire aussi

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

SpaceX Wants a 32-Mile Pipeline Tied Into Energy Transfer's and Kinder Morgan's Florida System. Does It Matter for Either Pipeline Stock?

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Partager

À lire aussi

Franco-Nevada Co. (FNV.TO) - What Are Researchers Thinking About This Stock?

RLI Non-GAAP EPS of $0.86 beats by $0.33, revenue of $476.9M beats by $9.8M

SpaceX Wants a 32-Mile Pipeline Tied Into Energy Transfer's and Kinder Morgan's Florida System. Does It Matter for Either Pipeline Stock?

Colleges raced to build massive computer-science departments. Now the boom is turning to bust.

First Solar leads green energy stocks on value and free cash flow

Anthropic is AI trade's last big hope for a major IPO this year